公开(公告)号：WO2009126307A2

公开(公告)日：2009-10-15

申请号：PCT/US2009/002248

申请日：2009-04-10

Applicant: CATALYST BIOSCIENCES, INC. ,  MADISON, Edwin, L. ,  THANOS, Christopher

Inventor： MADISON, Edwin, L. ,  THANOS, Christopher

IPC: C12N9/64

CPC classification number: C12N9/6437 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/00 ,  C12N15/62 ,  C12Y304/21021

Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor Vila and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract translation: 提供了修饰的因子VII多肽及其用途。 这种修饰的FVII多肽包括因子VIIa和其他形式的因子VII。 所提供的经修饰的FVII多肽是那些具有改变的活性，通常改变的促凝活性，包括增加的促凝活性。 因此，这些修饰的多肽是治疗剂。

公开(公告)号：WO2005123119A2

公开(公告)日：2005-12-29

申请号：PCT/US2005/020516

申请日：2005-06-10

Applicant: CATALYST BIOSCIENCES, INC. ,  THANOS, Christopher, D. ,  MADISON, Edwin, L.

Inventor： THANOS, Christopher, D. ,  MADISON, Edwin, L.

IPC: A61K38/48

CPC classification number: C12N9/6421 ,  A61K38/00 ,  C12N9/6494 ,  C12Y304/24011

Abstract: Administration of recombinant, truncated mammalian NEP or certain bacterial homologues of this protein is therapeutically effective in the treatment of inflammatory bowel disease.

Abstract translation: 重组，截短的哺乳动物NEP或该蛋白质的某些细菌同系物的施用在治疗炎症性肠病中是治疗有效的。

公开(公告)号：WO0220475A3

公开(公告)日：2003-08-14

申请号：PCT/US0128137

申请日：2001-09-07

Applicant: CORVAS INT INC ,  DUNCAN DAVID F ,  MADISON EDWIN L ,  SEMPLE JOSEPH EDWARD ,  COOMBS GARY SAMUEL ,  REINER JOHN EUGENE ,  ONG EDGAR O ,  ARALDI GIAN LUCA

Inventor： DUNCAN DAVID F ,  MADISON EDWIN L ,  SEMPLE JOSEPH EDWARD ,  COOMBS GARY SAMUEL ,  REINER JOHN EUGENE ,  ONG EDGAR O ,  ARALDI GIAN LUCA

IPC: C12N9/99 ,  A61K31/4436 ,  A61K31/55 ,  A61K38/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07C279/12 ,  C07D223/12 ,  C07D409/12 ,  C12N9/64 ,  A61K38/55 ,  C07C311/13 ,  C07D207/16 ,  C07K5/06

CPC classification number: C12N9/6424

Abstract: The present invention provides compounds which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compositions comprising those compounds and methods of using the compounds and pharmceutical compositions to treat conditions ameliorated by inhibition of matriptase or MTSP1.

Abstract translation: 本发明提供抑制matriptase或MTSP1的丝氨酸蛋白酶活性的化合物。 还提供了包含那些化合物的药物组合物和使用化合物和药物组合物来治疗通过抑制matriptase或MTSP1而改善的病症的方法。

公开(公告)号：WO2003044179A3

公开(公告)日：2003-05-30

申请号：PCT/US2002/037626

申请日：2002-11-20

Applicant: DENDREON SAN DIEGO LLC ,  MADISON, Edwin, L. ,  ONG, Edgar, O.

Inventor： MADISON, Edwin, L. ,  ONG, Edgar, O.

IPC: C12N9/64

Abstract: Provided herein are polypeptides designated CVSP17 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity therof are provided. The polypeptides also serve as tumor markers.

公开(公告)号：WO2003031585A3

公开(公告)日：2003-04-17

申请号：PCT/US2002/032417

申请日：2002-10-08

Applicant: DENDREON CORPORATION ,  MADISON, Edwin, L. ,  YEH, Jiunn-Chern

Inventor： MADISON, Edwin, L. ,  YEH, Jiunn-Chern

IPC: C12N9/64

Abstract: Provided herein are type I transmembrane serine protease 25 (MTSP25) polypeptides. Activated forms of these polypeptides and single and two chain forms of the protease domain are also provided. Methods using the polypeptides for therapeutic and diagnostic purposes are provided.

公开(公告)号：WO2002077263A2

公开(公告)日：2002-10-03

申请号：PCT/US2002/009039

申请日：2002-03-20

Applicant: CORVAS INTERNATIONAL, INC. ,  MADISON, Edwin, L. ,  YEH, Jiunn-Chern

Inventor： MADISON, Edwin, L. ,  YEH, Jiunn-Chern

IPC: C12Q

CPC classification number: C12N9/6408 ,  G01N2333/96433 ,  G01N2500/04 ,  Y10S436/809

Abstract: Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provides. The polypeptides also serve as tumor markers.

Abstract translation: 本文提供了称为CVSP14多肽的多肽，其表现出作为单链或活化的双链形式的蛋白酶活性。 提供了使用多肽来鉴定调节其蛋白酶活性的化合物的方法。 多肽也用作肿瘤标志物。

公开(公告)号：WO0157194A3

公开(公告)日：2002-03-28

申请号：PCT/US0103471

申请日：2001-02-02

Applicant: CORVAS INT INC ,  MADISON EDWIN L ,  ONG EDGAR O ,  YEH JIUNN CHERN

Inventor： MADISON EDWIN L ,  ONG EDGAR O ,  YEH JIUNN-CHERN

IPC: A01K67/027 ,  A61K38/48 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P9/14 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07K16/40 ,  C12M1/34 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/99 ,  C12N15/09 ,  C12P21/08 ,  C12Q1/37 ,  C12R1/19 ,  C12R1/84 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N37/00 ,  C07K19/00 ,  C12N15/57

CPC classification number: C12N9/6424 ,  C07K2319/00

Abstract: Provided herein are polypeptides that include the protease domain of a type II transmembrane serine protease (MTSP) as a single chain. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP are provided. Also provided are MTSPs designated MTSP3 and MTSP4 and a form of an MTSP designated MTSP6.

Abstract translation: 本文提供的是包含作为单链的II型跨膜丝氨酸蛋白酶（MTSP）的蛋白酶结构域的多肽。 提供了使用多肽来鉴定调节MTSP的蛋白酶活性的化合物的方法。 还提供了指定为MTSP3和MTSP4的MTSP以及指定为MTSP6的MTSP形式。

公开(公告)号：WO2012061654A1

公开(公告)日：2012-05-10

申请号：PCT/US2011/059233

申请日：2011-11-03

Applicant: CATALYST BIOSCIENCES, INC. ,  MADISON, Edwin, L. ,  THANOS, Christopher ,  BLOUSE, Grant, Ellsworth

Inventor： MADISON, Edwin, L. ,  THANOS, Christopher ,  BLOUSE, Grant, Ellsworth

IPC: C12N9/64

CPC classification number: C12N9/644 ,  A61K38/4846 ,  A61K48/00 ,  C12Y304/21022

Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract translation: 提供了修饰因子IX（FIX）多肽及其用途。 这种修饰的FIX多肽包括FIXa和其它形式的FIX。 提供的修饰的FIX多肽中的那些是具有改变的活性，通常改变的促凝活性，包括增加的促凝活性。 因此，这些修饰的多肽是治疗剂。

公开(公告)号：WO2007047995A2

公开(公告)日：2007-04-26

申请号：PCT/US2006/041165

申请日：2006-10-20

Applicant: CATALYST BIOSCIENCES, INC. ,  MADISON, Edwin, L. ,  NGUYEN, Jack ,  RUGGLES, Sandra, Waugh ,  THANOS, Christopher, D.

Inventor： MADISON, Edwin, L. ,  NGUYEN, Jack ,  RUGGLES, Sandra, Waugh ,  THANOS, Christopher, D.

IPC: A61K38/48 ,  C12N9/64 ,  C12N15/62 ,  C12N15/86 ,  C12N5/10

CPC classification number: A61K38/482 ,  A61K38/49 ,  C07K2319/00 ,  C12N9/6421 ,  C12N9/6424 ,  C12N9/6467 ,  C12Y304/21109

Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder.

Abstract translation: 提供了用于调节补体系统的方法和化合物。 具体而言，提供抑制补体活化的化合物，并提供促进补体活化的化合物。 由于它们对补体系统的作用，化合物是治疗剂。 因此，抑制补体激活的化合物可以用于治疗局部缺血和再灌注障碍，包括心肌梗塞和中风，败血症，自身免疫性疾病，炎性疾病和炎性组分疾病，包括阿尔茨海默氏病和其他神经退行性疾病。

公开(公告)号：WO2005041631A3

公开(公告)日：2005-11-03

申请号：PCT/US2004034836

申请日：2004-10-20

Applicant: DYAX CORP ,  DENDREON CORP ,  NIXON ANDREW ,  MADISON EDWIN L

Inventor： NIXON ANDREW ,  MADISON EDWIN L

IPC: A61K38/00 ,  A61K38/08 ,  A61K38/10

CPC classification number: C07K14/001 ,  A61K38/00

Abstract: The disclosure describes compounds that can include a peptide or Kunitz domain that binds endotheliase 1 (ET1). The compounds can be used, e.g., to reduce angiogenesis in a subject having or at risk for a neoplastic disorder, modulate the activity of an ET1-expressing cell, modulate proteolysis of a biological structure, detect endotheliase activity or protein in a sample, and detect ET1 protein in a subjects.

Abstract translation: 本公开描述了可以包括结合内皮酶1（ET1）的肽或Kunitz结构域的化合物。 该化合物可以用于减少患有或具有肿瘤性疾病风险的受试者的血管发生，调节表达ET1的细胞的活性，调节生物结构的蛋白水解，检测样品中的内皮酶活性或蛋白质，以及 检测受试者中的ET1蛋白。